Januvia - DPP-IV inhibitor for Type 2 Diabetes
Key Data:
Drug (Brand/Generic)
Januvia (sitagliptin)
Company / Licensee
Merck Sharp & Dohme Limited
Therapy Class
DPP-IV inhibitor
Product Description
Orally active inhibitor of DPP-IV enzyme
Current Indication
Type 2 diabetes
Market Sector
Diabetes
Development Status
Approved 2006 (US), 2007 (EU)
